1. Zhang, Qian, Tang, Donge, Zha, Aiyun, Zhang, Wei, Dai, Yong. 2022. NFE2L3 as a Potential Functional Gene Regulating Immune Microenvironment in Human Kidney Cancer. In BioMed research international, 2022, 9085186. doi:10.1155/2022/9085186. https://pubmed.ncbi.nlm.nih.gov/36337840/
2. Lukomska, Agnieszka, Frost, Matthew P, Theune, William C, Gupta, Mahit, Trakhtenberg, Ephraim F. 2024. Nfe2l3 promotes neuroprotection and long-distance axon regeneration after injury in vivo. In Experimental neurology, 375, 114741. doi:10.1016/j.expneurol.2024.114741. https://pubmed.ncbi.nlm.nih.gov/38395216/
3. Chen, Tingting, Xu, Bing, Chen, Hui, Zhang, Xizhi, Hua, Wei. 2022. Transcription factor NFE2L3 promotes the proliferation of esophageal squamous cell carcinoma cells and causes radiotherapy resistance by regulating IL-6. In Computer methods and programs in biomedicine, 226, 107102. doi:10.1016/j.cmpb.2022.107102. https://pubmed.ncbi.nlm.nih.gov/36108571/
4. Qian, Jinqin, Huang, Cong, Zhu, Zhenpeng, Zhang, Cuijian, Gong, Yanqing. . NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer. In Carcinogenesis, 43, 457-468. doi:10.1093/carcin/bgac006. https://pubmed.ncbi.nlm.nih.gov/35022660/
5. Ren, Yonggang, Yang, Jing, Ding, Zhiran, Tang, Aifa, Huang, Dandan. 2023. NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53. In Cancer science, 114, 3523-3536. doi:10.1111/cas.15887. https://pubmed.ncbi.nlm.nih.gov/37350063/
6. Wang, Hui, Zhan, Ming, Yang, Ruimeng, Liu, Qiang, Wang, Jian. 2018. Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. In Cell cycle (Georgetown, Tex.), 17, 2164-2174. doi:10.1080/15384101.2018.1520558. https://pubmed.ncbi.nlm.nih.gov/30196752/